



# Biotech Daily

Tuesday June 23, 2020

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH DOWN: NEUREN UP 8%; MESOBLAST DOWN 8%**
- \* **TALI: TALI DETECT VALID, RELIABLE ATTENTION DIAGNOSTIC**
- \* **ANATARA: NO DETACH PARTNER BY JULY**
- \* **INVION: NZ PATENT FOR PHOTODYNAMIC CANCER THERAPY**
- \* **CLIME TAKES 9.1% OF MACH7**
- \* **AUSTRALIAN ETHICAL TAKES 5.5% OF MACH7**
- \* **ELEANORE GOODRIDGE REDUCES TO 6.4% OF NOXOPHARM**
- \* **MGC: 3-YEAR GMP LICENCE FOR SLOVENIAN FACILITY**

## MARKET REPORT

The Australian stock market was up 0.17 percent on Tuesday June 23, 2020, with the ASX200 up 1.9 points to 5,944.5 points.

Ten of the Biotech Daily Top 40 stocks were up, 23 fell and seven traded unchanged.

Neuren was the best, up 12.5 cents or eight percent to \$1.69, with 207,533 shares traded. Kazia climbed 6.4 percent; Actinogen improved 4.2 percent; Compumedics and Imugene were up more than three percent; LBT and Nanosonics rose more than two percent; Genetic Signatures and Resmed were up more than one percent; with Clinuvel and Telix up by less than one percent.

Mesoblast led the falls, down 31 cents or 8.4 percent to \$3.39, with 16.6 million shares traded. Both Oncosil and Patrys lost 7.7 percent; Antisense was down 5.7 percent; Avita, Impedimed, Medical Developments, Opthea and Universal Biosensors fell more than four percent; Cyclopharm, Cynata, Ellex and Paradigm were down three percent or more; Pro Medicus, Resonance and Uscom shed more than two percent; Cochlear, Pharmaxis, Prescient and Proteomics were down by more than one percent; with CSL, Next Science, Polynovo, Starpharma and Volpara down by less than one percent.

## TALI DIGITAL

Tali says a study of 340 Victorian children has found that its Tali Detect psychometric attention assessment tool is valid, reliable and developmentally sensitive.

Tali said the study, conducted by Swinburne University of Technology, aimed to investigate the accuracy of Tali Detect on children between four and eight years in Victorian primary schools, kindergartens and childcare centres.

The company said Tali Detect was a game-based program that assessed sustained attention, selective attention and cognitive flexibility relative to a normative performance measure and took between 20 and 25 minutes.

Tali said it achieved its primary endpoint to determine the validity and reliability of Tali Detect and found that the six game-based cognitive subtests provided a foundational assessment of key attentional domains.

The company said the study showed that Tali Detect had an excellent factor structure, indicating that there was sufficient differentiation between factors for selective attention, sustained attention and cognitive flexibility.

Tali said the tests had good developmental sensitivity to account for age differences, with age positively associated with performance on selective attention ( $p < 0.001$ ), sustained attention ( $p < 0.001$ ) and cognitive flexibility ( $p < 0.001$ ).

The company said the study found that Tali Detect had scalar invariance, meaning that factor estimates did not change over time and showed high-retest reliability for sustained attention and selective attention, but not for cognitive flexibility.

Tali said cognitive flexibility was currently estimated using one indicator and it would add another cognitive task.

The company Tali Detect was available via mobile telephone software application websites and it expected to launch the product commercially from July 2020.

Tali was unchanged at 2.7 cents with 24.1 million shares traded.

## ANATARA LIFESCIENCES

Anatara says it does not expect to reach a partnering agreement for its pineapple-stem bromelain-derived Detach for livestock diarrhoea by June 30, 2020.

Last June, Anatara said the Florham Park, New Jersey-based Zoetis Inc had terminated its exclusive worldwide licence to the Detach diarrhoea treatment for livestock and horses (BD: Jun 14, 2019).

In August, the company said it had hired an animal health business development consultant to help licence Detach for piglet diarrhoea (BD: Aug 5, 2019).

Today, Anatara said it was in discussions with third parties to progress development of its animal health products and to address barriers to partnering.

The company said it continued to progress its human health portfolio and hoped to commence a trial of its gastrointestinal reprogramming (Garp) medicine for irritable bowel syndrome by December 31, 2020.

Anatara said that due to budgetary constraints, it was exploring animal health partner companies to develop and commercialize Detach for multiple species and was nearing conclusion of due diligence and negotiation.

The company said feedback suggested that further proof of concept data in other species and additional dosage forms for piglets was required.

Anatara fell half a cent or 3.2 percent to 15 cents.

## INVION

Invion says the New Zealand Patent Office has accepted a patent by RMW Cho Group for its photodynamic cancer therapy IVX-PDT, based on its Photosoft technology.

Invion said the patent, titled 'Chlorin derivative useful in photodynamic therapy and diagnosis' would protect its intellectual property until December 13, 2033.

The company said the patent related to "the chlorin e4 sodium photosensitizer and a process for its preparation" which had advantages over earlier photodynamic technologies, including deeper tissue penetration, more rapid clearance of cells and a lack of dark toxicity.

Invion said it expected the patent to be granted from September 26, 2020 provided there was no opposition or re-examination.

The company said RMW Cho Group funded its research and clinical trials through a research and development services agreement.

Last year, Unlimited Innovation Group and the Cho Group said they held 68 percent of Invion (BD: Aug 16, 2019).

Invion was up 0.1 cents or 14.3 percent to 0.8 cents with 2.3 million shares traded.

## MACH7 TECHNOLOGIES

Clime Investment Management says it has increased its substantial shareholding in Mach7 from 13,621,458 shares (7.45%) to 19,810,832 shares (9.11%).

The Sydney-based Clime said that between May 8 and June 18, 2020 it acquired 6,189,374 shares for between 55 and 89 cents a share in on-market sales and through the \$23.4 million placement and institutional rights offer (BD: Jun 12, 2020).

Mach7 was up two cent or 2.2 percent to 94 cents with 2.1 million shares traded.

## MACH7 TECHNOLOGIES

Australian Ethical Investment says it has become a substantial shareholder in Mach7 with 11,857,136 shares or 5.45 percent of the company.

The Sydney-based Australian Ethical said that between July 3 and October 17, 2019 it sold 3,719,081 shares for \$2,787,937 or 75.0 cents a share and between December 4, 2019 and June 15, 2020 it acquired 8,664,795 shares for \$5,626,090 or 64.9 cents a share.

Earlier this month, Mach7 said it had raised \$23.4 million through a placement and institutional rights offer at 68 cents a share and hoped to raise a further \$11.4 million through a retail rights offer (BD: Jun 12, 2020).

## NOXOPHARM

Eleanore Goodridge says she has reduced her substantial shareholding in Noxopharm from 17,705,340 shares (8.30%) to 13,574,144 shares (6.37%).

The Darling Point, New South Wales-based Ms Goodridge said that she sold 4,131,196 shares on in an off-market sale on June 18, 2020 at 13 cents a share.

Noxopharm fell one cent or 5.1 percent to 18.5 cents.

## MGC PHARMACEUTICALS

MGC says it has a further three-year good manufacturing practice licence for its Slovenian production and compounding facility.

MGC said the Slovenia Agency of Medicinal Products and Medical Devices conducted an annual audit and renewed the licence, confirming its compliance with European quality standards.

MGC was unchanged at 2.2 cents with 4.3 million shares traded.